Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diphencyprone for the Treatment of Alopecia Areata

Diphencyprone for the Treatment of Alopecia Areata EDITORIAL More Data and New Aspects NTHE August 2001 issue of the ARCHIVES, Wise- Wiseman et al found that concomitant administration of man et al presented new and interesting data an intralesional steroid, when performed in patients with obtained from a group of 148 consecutive pa- persistent patches of hairlessness, was associated with a tients who were treated with diphencyprone. The “significantly better therapeutic outcome.” We have never I authors provide convincing evidence that this performed this additional treatment in patients receiv- therapeutic modality is associated with a high rate of sat- ing diphencyprone, and I hesitate to conclude that con- isfactory responses that cannot be equaled by any other comitant intralesional steroid therapy, a modality that cer- known treatment. tainly interferes with the action of the contact allergen, I agree with the authors that the large range of success can be taken as a favorable prognostic factor with re- rates published in previous studies can be attributed to a gard to diphencyprone treatment. lack of uniform definition for “response.” Wiseman et al Another perplexing result reported by Wiseman et al defined a clinically substantial response as “significant re- refers to the risk of relapse at long-term follow-up. After http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Diphencyprone for the Treatment of Alopecia Areata

JAMA Dermatology , Volume 138 (1) – Jan 1, 2002

Loading next page...
 
/lp/american-medical-association/diphencyprone-for-the-treatment-of-alopecia-areata-qBTxqFbciV
Publisher
American Medical Association
Copyright
Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/archderm.138.1.112
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL More Data and New Aspects NTHE August 2001 issue of the ARCHIVES, Wise- Wiseman et al found that concomitant administration of man et al presented new and interesting data an intralesional steroid, when performed in patients with obtained from a group of 148 consecutive pa- persistent patches of hairlessness, was associated with a tients who were treated with diphencyprone. The “significantly better therapeutic outcome.” We have never I authors provide convincing evidence that this performed this additional treatment in patients receiv- therapeutic modality is associated with a high rate of sat- ing diphencyprone, and I hesitate to conclude that con- isfactory responses that cannot be equaled by any other comitant intralesional steroid therapy, a modality that cer- known treatment. tainly interferes with the action of the contact allergen, I agree with the authors that the large range of success can be taken as a favorable prognostic factor with re- rates published in previous studies can be attributed to a gard to diphencyprone treatment. lack of uniform definition for “response.” Wiseman et al Another perplexing result reported by Wiseman et al defined a clinically substantial response as “significant re- refers to the risk of relapse at long-term follow-up. After

Journal

JAMA DermatologyAmerican Medical Association

Published: Jan 1, 2002

References